Investor_Tester
21 Sep 2015
Re: Good progress...but can do more Hi N&SI wouldn't be too concerned , if anything shows you what the future potential of ANGLE is with Parsortix.EKF's Pointman more aimed at enriching DNA samples than the trapment oof cancer cells in blood samples that our Parsortix offersEKFs is under offer too. , which is interesting.You're right though , ANGLE needs to start making some money now , as I'd hate for them to milk us PIs again with another placement.Slow moving , but like I said , good opp to continue building a nest egg here.....we only fractionly higher in market value to last year this time.GL eitherway and looking forward to further good news soonIT
niceandsimple
18 Sep 2015
Re: Good progress...but can do more Hi ITbit concerned with EKF's Pointman RNS today - appears not to include our product. If it can be used for lung cancer what about other CTC's? I appreciate all products have competition but any thoughts - are we now in a race to market?We need sales news Andrew.CheersN&S
Investor_Tester
17 Sep 2015
Good progress...but can do more Nice posts niceandsimple....see not much activity on this BB apart from you and I and a small handfuls of others.I noticed a post by AstraZeneca that 90% of Ovarian Cancer sufferers live longer than 5years.....I was very tempted to advise on Parsotix..as earlier diagnosis would dramatically increase both the chance to treat better , but also lengthen sufferers life.I know ANGLE has an amazing product here and seems like the world in is the dark on this....maybe a good thing for us to pile up on shares before a massive re-rate or buyout.I am still in the belief that once the FDA approval comes along , this share is going to catapult to some dizzy highs.For now , the SP is relatively stable and I'm happy to drip in some regular purchases whilst these levels remain as is.GLA ....our time will come to celebrate soon enough IT
niceandsimple
17 Sep 2015
Cancer drug budgets [link] Angle have the answer?N&S
niceandsimple
13 Sep 2015
Surely Angle can play a part[link]
niceandsimple
07 Sep 2015
Come on Angle [link]
niceandsimple
30 Aug 2015
[link] CTCs are living cells they may be more reflective of future progression of the disease (looking through the front windscreen) than ctDNA, which are fragments of dead cells (looking in the rear view mirror)....."Says it all - and yes the operative word is 'may'. The Living CTC count surely has the advantage for both the 'as is' examination of the patient and thereafter the effectiveness of medicine on the CTC's.Just in my uneducated opinion / judgementAll the bestN&S
autpaxautbellum
30 Jul 2015
Nice - AGL involved with CRUK Cambridge so not a wild assumption that Parsortix could become, or might be already, useful in the project.
niceandsimple
30 Jul 2015
Prostrate Cancer [link] anyone else envisage our 'liquid biopsy' playing a part in this advance?The following is an extract from Angle's recent prostrate cancer RNS:"...PARSORTIX SYSTEM HARVESTS CTCS IN 100% OF PROSTATE CANCER PATIENTSBarts study demonstrates Parsortix harvested cells are clinically relevant in prostate cancer Dr Yong-Jie Lu, Reader in Medical Oncology at Barts Cancer Institute, commented: "This work has confirmed the ability of the Parsortix system to harvest clinically relevant mesenchymal cells and that these cells correlate with the patient PSA level, the current gold standard for assessing whether the patient's prostate cancer is progressing. We are looking forward to the next stage of the work investigating molecular biomarkers on the harvested cells and hope that this may help guide effective treatment for prostate cancer patients in the future." ANGLE Founder and Chief Executive, Andrew Newland, commented:"The prospect of deployment of our repeatable, non-invasive liquid biopsy in the treatment of prostate cancer patients in therapy selection and remission monitoring is exciting. These findings are encouraging and we look forward to further developments as soon as possible." All the bestN&S
niceandsimple
25 Jul 2015
Its slowly getting nearer the near term triggers for me (from the 23rd July RNS) were1: ".....The cancer cells obtained from patient blood using the Parsortix system can be analysed using existing molecular analysis platforms already installed worldwide in hospital pathology laboratories for analysis of solid biopsy material. It is therefore in the interests of the companies that own these systems to promote the use of the Parsortix system as a front end for their own platforms as this will generate additional sales for them from their existing installed platform.This process is underway with the first two corporate collaborations initiated during the year......"2:".....We estimate that the research use sales market is worth approximately £250 million per annum and aim to commence sales into this market in the current financial year....."and finally3:"......ANGLE has taken on additional external support from a number of leading experts with a track record of successful FDA authorisations for similar diagnostic systems. Whilst some additional studies are still required, we remain positive about the prospect of achieving FDA authorisation......"152 days to xmas - would be fantastic if all three materialised as a present for us shareholdersAll the bestN&S
broomfielder
23 Jul 2015
Financial Results I am still looking at the Figures in detail but they do not seem to be well received in the Market with the SP down over 6% at this time.Fully funded for the year ahead I note any calendar reference to the hoped for US regulatory approvals has now been removed (previously indicated it should within current year). I appreciate the Co cannot really influence the timescale but it may indicate slippage and/or less certainty of approval.Also now with Parsortix becoming the sole focus of the Company while its prospects look potentially transformational, it arguably puts our eggs very much into one basket.Finally, the large scale patient study across US and Europe I see is being pencilled in to complete by end 2016. A huge project no doubt but is this further potential slippage?Meantime losses are to be expected but the acidtest is the Company's (correct in my view) move toward commercialising Parsortix through sales to Research practitioners as clearly end cliniçal sales could now be c2 years away at the earliest.Hopefully the US approvals come through in the next 6 months which could the generate some M & A activity as a major player would then be interested provided we also tie up the US Patents as well.B
autpaxautbellum
20 Jul 2015
Progress Things all starting to come together with wide spread of scientific advisors.With a bit of luck the results will pull everything together and add a bit more.
millwallfan
12 May 2015
Re: It makes you wonder The article is dated 27 April so very recent. With relatively so few shares in circulation any ii investment from a major pharma would have to be recorded via an RNS (which I have not seen ) but would certainly underpin the recent rise if forthcoming through some stake building. If the current progress and success rate is sustained then when full approval is received I agree we could be in for an interesting year or so. Not a direct comparator but look at the 5 year chart of GWP to se how quickly pharma companies can move in a short period after long term at lowere levels. I think I will keep the faith as my average on a small holding is only 50p. Other views welcome.
18pcnt
11 May 2015
Re: It makes you wonder If you haven't seen this, watch it![link] who thinks this is just corporate spin... Here is a non-Angle interview with Prof. Zeillinger, Head of the Molecular Oncology Group, Medical University of Vienna.[link] of my favourite quotes:"...unprecedented high detection rate of cancer, even in early stage patients, when conventional diagnostic methods failed"“The Parsortix technology contributes to the unprecedented specificity of the overall approach, by providing a high purity CTC sample. Parsortix is a label-free technology, and as such may become the gold standard for ovarian cancer diagnosis,” "We already have five Parsortix systems with more to come... without this technology our research would still be where it was three years ago"“It is now clear that the Parsortix system has wide application not just in ovarian cancer but in breast cancer and other gynecological cancers as well,” noted Zeillinger. “We are delighted to be working with ANGLE to bring this new capability to our patients as soon as possible.”
18pcnt
11 May 2015
Re: It makes you wonder Nope. Seems straight forward. Market cap is only 54m quid. Look at the tech. Look at the potential. In my humble opinion, very cheap at current price. Without news, I can see this at 100m (2 quid/share). Far beyond that on favourable news. Look at other pre-sales aim shares bought on basis of tech potential. Xeros (200m)... Tissue Regenix (160m)... sure you can contnue listing them...I know nothing though so... do your own research and make your choice... Im in up to my eyeballs 
